DiaSorin S.p.A.

Equities

DIA

IT0003492391

Medical Equipment, Supplies & Distribution

Real-time Borsa Italiana Other stock markets 05:21:32 2024-04-26 am EDT			5-day change	1st Jan Change
94.7 ^EUR	+1.11%		+3.86%	+1.57%

Apr. 24	Citadel Advisors initiates short on STMicroelectronics.	AN
Apr. 23	Reduced a short on DiaSorin, increased on STM.	AN

DiaSorin S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021

March 15, 2022

DiaSorin S.p.A. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 1,237.7 million compared to EUR 881.3 million a year ago. Net income was EUR 310.7 million compared to EUR 248.3 million a year ago.

Latest news about DiaSorin S.p.A.

Citadel Advisors initiates short on STMicroelectronics.	Apr. 24	AN
Reduced a short on DiaSorin, increased on STM.	Apr. 23	AN
Futures up; wait for Eurozone PMI	Apr. 23	AN
Mib bearish; DiaSorin closes ahead of all	Apr. 22	AN
Marble Bar Asset Management cuts short on OVS.	Apr. 19	AN
Marshall Wace moves on Leonardo and OVS.	Apr. 18	AN
More buying on stock markets; MFE good after accounts	Apr. 18	AN
Traders ignore Powell; Popolare Sondrio bullish	Apr. 17	AN
Mib up; DiaSorin leads the way	Apr. 17	AN
Mib above 34,100 ahead of Italian retail sales	Apr. 10	AN
Futures await stock exchanges on U.S. pre-inflation	Apr. 10	AN
Stock markets down; gold still record high	Apr. 09	AN
Millennium International cuts short on DiaSorin	Apr. 09	AN
Mib correction at 34,000; strength on Fincantieri	Apr. 09	AN
Lists bearish; DiaSorin rises against the tide	Apr. 09	AN
Mib bullish; Interpump confirms top spot	Apr. 08	AN
Lists up slightly; Interpump best performer	Apr. 08	AN
Stevanato Group Names Ugo Gay as Chief Operations Officer	Apr. 04	MT
Envestra and JPMorgan change positions on De Nora	Apr. 04	AN
Stock markets in green ahead of Eurozone macros	Apr. 04	AN
JPMorgan revises three bearish positions.	Apr. 02	AN
Mib rises to 34,700; Iveco at annual high	Mar. 26	AN
Mib still bullish; Rai Way bullish after accounts	Mar. 26	AN
BlackRock and Capital Fund exceed 0.5 percent on TIM	Mar. 21	AN
Futures up sharply; wait for BoE	Mar. 21	AN

Chart DiaSorin S.p.A.

Duration

Period

More charts

Company Profile

DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc. At the end of 2023, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-09 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE MIB INDEX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

DIASORIN : Profitability guidance miss; dreams inching towards reality

March 18, 2024 at 05:24 am EDT

More Strategies

Ratings for DiaSorin S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

93.66 EUR

Average target price

97.41 EUR

Spread / Average Target

+4.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
DIASORIN S.P.A.	+1.57%	5.35B
BIOMÉRIEUX	-0.75%	12.59B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-12.53%	7.42B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.37%	4.51B
LANTHEUS HOLDINGS, INC.	+5.16%	4.47B
10X GENOMICS, INC.	-51.93%	3.21B
ANDON HEALTH CO., LTD.	+11.34%	2.71B
VITROLIFE AB	-18.28%	1.96B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.07%	1.73B
MYRIAD GENETICS, INC.	-6.06%	1.63B

Diagnostic & Testing Substances